RxDoctor Payments Data

Calvin Walker, MD

Psychiatry · Monroe, LANPI 1710941737

Payments from drug & device makers

$1,909in general payments, 2019–2025

Across 117 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$371
  • Takeda Pharmaceuticals U.S.A., Inc.$303
  • Teva Pharmaceuticals USA, Inc.$266
  • AbbVie$217
  • Tris Pharma Inc$145
  • Neurocrine Biosciences, Inc.$139
  • plus $467 from 6 others

What the payments were for

  • Food & beverage$1,902100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,909 in reported general payments places this provider in the 70th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Medicare billing

Part B allowed, 2024
$11,319
Medicare patients
40
Services billed
83

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate30$53,194
Lurasidone Hcl40$13,807
VyvanseLisdexamfetamine Dimesylate13$4,813
Lisdexamfetamine Dimesylate20$3,996
Risperidone OdtRisperidone16$2,063
Oxcarbazepine41$2,046
Quetiapine Fumarate66$1,934
Divalproex Sodium ErDivalproex Sodium37$1,510
Mirtazapine42$963
Duloxetine Hcl43$893
Gabapentin27$836
Eszopiclone37$687
Trazodone Hcl41$620
Ropinirole Hcl39$576
Metformin Hcl ErMetformin Hcl21$442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$371$53,19430 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$303$4,81313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →